These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
297 related items for PubMed ID: 16638934
1. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG. Blood; 2006 Sep 01; 108(5):1469-77. PubMed ID: 16638934 [Abstract] [Full Text] [Related]
2. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG. Blood; 2007 Jul 15; 110(2):727-34. PubMed ID: 17405907 [Abstract] [Full Text] [Related]
3. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Cheng Z, Zhao L, Chen G, Wu D, Qiu H, Tang X, Fu C, Jin Z, Chen F, Xue S, Sun A. Zhonghua Xue Ye Xue Za Zhi; 2014 Feb 15; 35(2):114-9. PubMed ID: 24606651 [Abstract] [Full Text] [Related]
9. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, Lee JW, Min WS, Kim CC. Blood; 2005 May 01; 105(9):3449-57. PubMed ID: 15657178 [Abstract] [Full Text] [Related]
12. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK, Gehrke B, Gschaidmeier H, Hoelzer D, Ottmann OG. Blood; 2003 Jan 01; 101(1):85-90. PubMed ID: 12393581 [Abstract] [Full Text] [Related]
13. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Blood; 2015 Jun 11; 125(24):3711-9. PubMed ID: 25878120 [Abstract] [Full Text] [Related]
14. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Blood; 2004 Jun 15; 103(12):4396-407. PubMed ID: 14551133 [Abstract] [Full Text] [Related]
17. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY, Kim CC. Blood; 2003 Oct 15; 102(8):3068-70. PubMed ID: 12842984 [Abstract] [Full Text] [Related]
18. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. J Clin Oncol; 2010 Aug 01; 28(22):3644-52. PubMed ID: 20606084 [Abstract] [Full Text] [Related]